MedPath

Ocugen to Highlight Retinal Gene Therapy Progress at Clinical Showcase

• Ocugen will present updates from the Phase 3 liMeliGhT trial for retinitis pigmentosa and new data from Phase 1/2 trials on November 12, 2024. • Preliminary safety and efficacy data from the Phase 1/2 ArMaDa clinical trial for geographic atrophy will be shared at the event. • The showcase will also feature a clinical update on the Phase 1/2 GARDian clinical trial for Stargardt disease, offering insights into the therapy's progress. • Ocugen plans to initiate the OCU200 Phase I clinical trial this quarter for diabetic macular edema.

Ocugen, Inc. (NASDAQ: OCGN) will host an in-person Clinical Showcase on November 12, 2024, in New York City, highlighting advancements in its retinal gene therapy programs. The event will feature updates from ongoing clinical trials, including those for retinitis pigmentosa (RP), geographic atrophy (GA), and Stargardt disease.
The showcase will provide a clinical update on the Phase 3 liMeliGhT trial for retinitis pigmentosa, along with new data from Phase 1/2 trials for RP and Leber congenital amaurosis (LCA). Preliminary safety and efficacy data from the Phase 1/2 OCU410 ArMaDa clinical trial for geographic atrophy will also be presented.

Updates on Stargardt Disease and Diabetic Macular Edema

Ocugen will also share a clinical trial progress report from the Phase 1/2 OCU410ST GARDian study for Stargardt disease. In addition, the company will provide background information on its biologic candidate, OCU200, for diabetic macular edema, with plans to initiate a Phase I clinical trial this quarter.

Expert Insights and Patient Perspectives

The event will feature presentations from Ocugen's leadership team, including Dr. Shankar Musunuri, Chairman, CEO & Co-founder; Dr. Huma Qamar, Chief Medical Officer; and Dr. Arun Upadhyay, Chief Scientific Officer & Head of R&D. Study investigators, such as Dr. Benjamin Bakall, Dr. Lejla Vajzovic, and Dr. Syed M. Shah, will also participate. The program will conclude with a patient panel representing participants in Ocugen’s ongoing clinical trials, offering valuable perspectives on their experiences.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Ocular Therapeutix to Present AXPAXLI Update at J.P. Morgan Healthcare Conference

Ocular Therapeutix will present its 2025 strategic outlook at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025.
An update on the enrollment status of the SOL-R trial, evaluating AXPAXLI for wet AMD, will be provided during the presentation.

Ocugen Q3 2024 Earnings Highlight Clinical Progress in Gene Therapy

Ocugen, Inc. reported its Q3 2024 earnings, emphasizing significant advancements in its gene therapy programs, particularly for retinitis pigmentosa and other eye diseases. Despite a slight stock price decline, the company is making strides in clinical trials, including expansion into Canada and FDA approval for an expanded access program. Financials show a cash position of $39 million and operating expenses of $14.4 million, with a recent $30 million debt financing extending the company's runway into Q1 2026.

Ocugen's OCU400 Shows Promise in Retinitis Pigmentosa Treatment with Positive Clinical Data and Regulatory Milestones

Ocugen's OCU400 gene therapy demonstrated a statistically significant improvement in low-luminance visual acuity in patients with retinitis pigmentosa (RP).
The European Medicines Agency (EMA) has granted OCU400 an Advanced Therapy Medicinal Product (ATMP) classification, expediting its regulatory review process.

Macular Telangiectasia Cell Therapy NT-501 Achieves Primary Endpoints in Phase 3 Trials

NT-501, an encapsulated cell therapy, has demonstrated success in treating macular telangiectasia type 2 by meeting its primary endpoints in two phase 3 clinical trials.
The therapy offers a potential new approach for patients with this rare retinal disease, addressing an area of unmet medical need.

Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit - Quantisnow

Floretina ICOOR 2024: Updates on Stargardt Disease, AMD, and Wet AMD Therapies

Alkeus Pharmaceuticals shared results from TEASE studies, showing that gildeuretinol (ALK-001) significantly reduced the growth rate of retinal atrophic lesions in Stargardt disease patients.
Annexon presented data from the Phase 2 ARCHER trial, indicating that ANX007 provides significant vision protection and photoreceptor preservation in dry AMD patients with geographic atrophy.

Emerging Therapies Offer Hope for Geographic Atrophy Treatment

Several therapies are under evaluation in clinical trials for geographic atrophy (GA) secondary to age-related macular degeneration (AMD), addressing the unmet need for effective treatments.
Complement pathway inhibitors like ANX007, danicopan, and AVD-104 are being investigated to modulate the inflammatory response and cell lysis associated with GA progression.

Ocugen to Highlight Retinal Gene Therapy Progress at Clinical Showcase

Ocugen will present updates on the Phase 3 liMeliGhT trial for retinitis pigmentosa and new Phase 1/2 data on November 12.
Preliminary safety and efficacy data from the Phase 1/2 ArMaDa trial for geographic atrophy will be shared during the showcase.

AAO 2024: Emerging Data in Retinal Therapies for Geographic Atrophy, Stargardt Disease, and Retinitis Pigmentosa

Alkeus Pharmaceuticals will present results from clinical studies of oral gildeuretinol for geographic atrophy secondary to age-related macular degeneration (SAGA) and Stargardt disease (TEASE).
Annexon will share new analyses of ANX007 from the Phase 2 ARCHER trial in geographic atrophy, highlighting clinical results and anatomical changes.

Ocugen Highlights Modifier Gene Therapy Platform at Cell & Gene Meeting on the Mesa

Ocugen's CEO, Dr. Shankar Musunuri, presented the company's modifier gene therapy platform at the 2024 Cell & Gene Meeting on the Mesa.
The presentation included updates on OCU400 for retinitis pigmentosa (Phase 3), OCU410 for geographic atrophy (Phase 2), and OCU410ST for Stargardt disease (Phase 1/2).

Reference News

[1]
Ocugen Clinical Showcase Highlighting Progress in Retinal - GlobeNewswire
globenewswire.com · Oct 28, 2024

Ocugen to host Clinical Showcase on Nov 12, 2024, at Nasdaq MarketSite, focusing on updates from ongoing gene therapy tr...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy